We derive optimal designs to estimate efficacy and toxicity in active controlled dose-finding trials when the bivariate continuous outcomes are described using nonlinear regression models. We determine upper bounds on the required number of different doses and provide conditions under which the boundary points of the design space are included in the optimal design. We provide an analytical description of minimally supported optimal designs and show that they do not depend on the correlation between the bivariate outcomes.
INTRODUCTION
Most literature on optimal design of experiments concerns univariate outcomes. In practice, however, experiments are often conducted to measure multiple outcomes that may be correlated. For instance, pharmaceutical dose-finding trials invariably measure bivariate outcomes involving efficacy and toxicity. Heise & Myers (1996) used the Gumbel bivariate binary quantal response model and Magnusdottir (2013) applied c-optimal designs to the bivariate Emax model to study efficacy and toxicity. Similarly, Fan & Chaloner (2004) proposed using a continuation ratio model for a trinomial outcome, where the outcome of a patient is classified as no reaction when neither toxicity nor efficacy occurs, efficacy for efficacy without toxicity, and adverse reaction for toxicity. Adaptive dose-finding trials incorporating both efficacy and safety have also been investigated; see for example, Dragalin et al. (2008) .
Recently, the use of active controls instead of placebos in dose-finding trials has received considerable attention (Temple & Ellenberg, 2000; Splawinski & Kuzniar, 2004; Helms et al., 2015) . Dette et al. (2014 Dette et al. ( , 2015 discussed design issues for such trials with univariate outcomes. To the best of our knowledge, however, the problem of determining optimal designs for active controlled trials with bivariate mean outcomes has not yet been investigated. In this paper we address this problem in two steps. In § 3 we provide new results about optimal designs for various models with efficacy and toxicity outcomes without an active control. In particular we derive new upper bounds on the required number of doses and determine analytically the optimal designs with the minimum number of doses. Secondly, we show in § 4 how to obtain locally optimal designs for active controlled dose-finding trials from the preceding results for uncontrolled trials and demonstrate our approach in an example.
OPTIMAL DESIGNS FOR BIVARIATE OUTCOMES
Given a statistical model defined on a dose interval D = [L, R] ⊂ R + 0 , the design problem is to determine for a given design criterion the optimal number of doses, k, the dose levels d 1 , . . . , d k ∈ D, and the number of patients assigned to each dose. That is, for a given total sample size n 1 , the optimal design needs to specify the number of patients n 1i at each dose level d i subject to k i=1 n 1i = n 1 . We use the index 1 here in the notation, i.e., n 1 , n 1i , . . ., since in later sections we use the index 2 for active controlled clinical trials.
Let Y ij be the two-dimensional outcome variable at dose level d i from subject j and assume that
The mean response We further assume that η 1 is continuously differentiable with respect to the parameter θ 1 and denote, respectively, the gradients of the two mean responses with respect to θ e 1 and θ
Throughout, let 0 q denote the q-dimensional vector with all entries equal to 0; sometimes the subscript will be omitted for simplicity. The Fisher information matrix is given by the s 1 × s 1 matrix
where
and the blocks in the matrix are defined by
. We have suppressed the dependence of the matrices F, F 1 , F 2 and F 3 on the parameter θ 1 in our notation.
We consider approximate designs in the sense of Kiefer (1974) , which are defined as probability measures with finite support on the design space D. If an approximate design ξ has k support points, say d 1 , . . . , d k , with corresponding positive weights ω 1 , . . . , ω k such that k i=1 ω i = 1, and n 1 observations can be taken, a rounding procedure is applied to obtain integers n 1i (i = 1, . . . , k) from the possibly rational numbers ω i n 1 . The information matrix M 1 (ξ , θ 1 ) of a design ξ is defined by the s 1 × s 1 matrix
where the matrix F(d) is defined in (2). Under standard regularity conditions, the maximum likelihood estimatorθ 1 is asymptotically normally distributed, that is,
1 (ξ , θ 1 )} as n 1 tends to infinity. Consequently, we search for designs that maximize the information matrix M 1 (ξ , θ 1 ) in an appropriate sense. To be precise, let p ∈ [−∞, 1) and let K ∈ R s 1 ×m be a given matrix of full column rank. A design ξ * is called locally φ p -optimal for estimating the linear combination
T θ 1 is estimable by the design ξ (Kiefer, 1974) . Here, tr(A) and A − denote the trace and a generalized inverse of the matrix A, respectively.
One key advantage of working with approximate designs is that convex optimization theory can be applied and a general equivalence theorem is available to verify whether a design is optimal among all designs. Its proof is a direct application of Theorem 7.14 in Pukelsheim (2006) . 
and only if there exists a generalized inverse G of the information matrix M
1 (ξ * , θ 1 ) such that τ (d, ξ * ) = tr I 1 (d, θ 1 )GK{C K (ξ * )} p+1 K T G T − tr{C K (ξ * )} p 0 (3) holds for all d ∈ D, where C K (ξ * ) = {K T M − 1 (ξ * , θ 1 )K} −1 . If p = −∞, a design ξ * with Range(K) ⊂ Range{M 1 (ξ * , θ 1 )} is locally φ −∞ -optimaltr I 1 (d, θ 1 )GKC K (ξ * )EC K (ξ * )K T G T − λ min {C K (ξ * )} 0 holds for all d ∈ D, where λ min {C K (ξ * )} denotes the minimum eigenvalue of C K (ξ * ). Moreover,
at the support points of any φ p -optimal design there is equality in the above inequalities.
The sensitivity function on the left-hand side of (3) can be used to provide a lower bound on the φ pefficiency of any design for p > −∞ (Dette, 1996) , that is,
Characterizations of the type (3) are also useful for finding optimal designs analytically if the model is not too complicated. However, regression models with a multivariate outcome are complex and in practice optimal designs have to be found numerically (Chang, 1997; Sagnol, 2011) . For such calculations, sharp bounds on the number of support points of the optimal designs reduce the complexity of the optimization problem substantially and will be derived in the following section.
OPTIMAL DESIGNS FOR DOSE-FINDING TRIALS WITHOUT AN ACTIVE CONTROL
3·1. Introduction A design ξ 1 is called admissible if there does not exist a design ξ 2 such that
1 ) with respect to the Loewner ordering (Karlin & Studden, 1966) . Recently, the characterization of the number of support points of admissible designs has received considerable attention (Yang & Stufken, 2009; Yang, 2010; Dette & Melas, 2011; Yang & Stufken, 2012; Dette & Schorning, 2013) , leading to substantially smaller bounds than provided by the classical approach using Caratheodory's theorem (Pukelsheim, 2006) . We show in Theorem A.1 of the Supplementary Material that these results can be proved under weaker assumptions than usually made in the literature using the theory of Tchebycheff systems (Karlin & Studden, 1966) . More specifically, in Theorem A.1 we provide a characterization of admissible designs that generalizes Theorem 3.1 in Dette & Melas (2011) and can be used to derive new bounds on the number of support points of admissible designs for the commonly used nonlinear regression models in dose-finding trials without an active control for joint efficacy-toxicity outcomes.
3·2. Bounds on the number of support points
The function which maps the matrix M to (
is increasing with respect to the Loewner ordering on the set of all s 1 × s 1 matrices satisfying Range(K) ⊂ Range(M ) (Pukelsheim, 2006) 
THEOREM 2. Assume that the model for efficacy is given by
there exists a design ξ * with at most three support points such that 
2 , then it follows from Theorem 2(b) that for any design ξ there exists a design ξ * with at most five support points such that
, then ξ * can be chosen such that its support contains L and R. The other cases are obtained similarly.
3·3. Minimally supported D-optimal designs
Let # supp(ξ ) denote the number of support points of a design ξ and let m * = min{# supp(ξ ) | det{M 1 (ξ , θ 1 )} > 0, ξ is a design on D} be the minimal number of support points of a design with a nonsingular information matrix in model (1). A design ξ is called minimally supported if det{M 1 (ξ , θ 1 )} > 0 and the number of support points is given by m * . In general, optimal designs have to be determined numerically for complex models, and even then many current algorithms may not work well. However, restricting the search to minimally supported designs can greatly simplify the optimization problem, which may then allow us to determine locally D-optimal designs. The following result provides minimally supported D-optimal designs for some dose-response models. Its proof uses Theorem 4, which reduces the optimization problem to the determination of the support points. Here and elsewhere, we let a ∨ b denote the maximum of the two numbers in the set {a, b}. 
THEOREM 4. If the number of parameters in the mean function for the efficacy model is the same as
(i) If η t 1 (d, θ t 1 ) = ϑ t 0 + ϑ t 1 d + ϑ t 2 d 2 ,
the minimally supported D-optimal design is a three-point design with equal masses at the points L, (L + R)/2 and R.
( 
the minimally supported D-optimal design is a three-point design with equal masses at the points
and R.
OPTIMAL DESIGNS FOR ACTIVE CONTROLLED DOSE-FINDING TRIALS
We now extend the preceding results to active controlled dose-finding trials with a predetermined total number of patients N by determining the optimal number k of different dose levels for the new drug, their individual dose levels d 1 , . . . , d k , and the optimal number n 1 of patients to be assigned to the new drug, along with the allocation scheme across the recommended doses. The remaining number n 2 = N − n 1 of the patients are assigned to the active control, usually a marketed drug administered at a fixed dose level C. Thus, we have designs of the form
whereω i andω k+1 denote the proportion of patients treated at the ith dose level of the new drug (i = 1, . . . , k) and with the active control, respectively; thus, n 2 ≈ω k+1 N . The second component of the design points in (4) specifies whether patients receive the new drug, 0, or the active control, 1. Note that the approximate designξ induces an approximate design of the form
for the new drug by defining ω i =ω i /(1 −ω k+1 ). Extending the statistical model from Dette et al. (2014) to the efficacy-toxicity outcomes considered here, we have
where Y ij denotes the outcome of the jth patient treated with the new drug at dose level d i , and Z j the outcome from the jth patient treated with the active control. The two-dimensional vector η 2 (θ 2 ) is the expected outcome, where the parameter θ 2 varies in a compact parameter space, say 2 ⊂ R 2 , and 2 is a 2 × 2 covariance matrix. The function η 2 that maps 2 to R 2 is assumed to be continuously differentiable. Assuming that all observations are independent, the information matrix of a designξ defined in (4) has a block structure of the form
is the 2 × 2 Fisher information matrix corresponding to the active control. Following Dette et al. (2015) , locally optimal designs for active controlled dose-finding trials can be obtained from locally optimal designs for dose-finding trials without an active control. We extend this result to the class of admissible designs introduced in the preceding sections.
THEOREM 6. If ξ is an admissible design of the form (5) in model (1) andω k+1 ∈ (0, 1), the designξ defined in (4) is an admissible design for the model (6) with an active control (7).
In a similar way, φ p -optimal designs for active controlled trials with efficacy-toxicity outcomes can be obtained. For this purpose we state the following result, which can be proved in a similar way to Theorem 1 in Dette et al. (2015) using the block structure of the matrix M (ξ , θ) in (8) 
) and (C, 1), respectively, is locally φ p -optimal in the dose-response model (6) with an active control (7), where
Theorem 7 can be extended to construct minimally supported designs. In particular, any minimally supported φ p -optimal design of the form (5) for the dose-response model (6) yields a minimally supported φ p -optimal design for the dose-response model (6) with an active control (7) by the transformation described in Theorem 7. T and an Emax model with parameter θ t 1 = (0·1, 2·4, 1·2) T , respectively; see Jin & Barker (2016) and Thomas & Roy (2017) for the choice of dose-response models in clinical trials. Assume further that σ e = 0·1 and σ t = 0·4. It follows from Theorem 2(b) and Theorem 6 that only designs with at most six support points have to be considered for the corresponding model with an active control. We first used a metaheuristic particle swarm optimization algorithm to generate the locally D-optimal design for model (1); see Wong et al. (2015) for an explanation of the algorithm. We then applied Theorem 7 to determine the locally optimal design for the model with an active control. The results for the locally D-optimal designs are listed in the left part of Table 1 for ρ = 0·1, 0·5, 0·9. The D-optimal designs are not minimally supported and the support points and weights depend on the correlation. The minimally supported D-optimal designs can be found by an application of Theorem 5 and are presented in the right part of Table 1. Note that these designs do not depend on ρ since they are equally weighted Table 1 for (a) ρ = 0·1, (b) ρ = 0·5 and (c) ρ = 0·9.
by Theorem 4. The optimality of the numerically calculated locally D-optimal designs was checked by Theorem 1 and the corresponding sensitivity functions are displayed in Fig. 1 for different values of the correlation. All designs calculated by the particle swarm optimization algorithm are in fact D-optimal. Moreover, the minimally supported designs are not optimal and their D-efficiencies are given by 0·97, 0·95 and 0·82 for the cases ρ = 0·1, 0·5 and 0·9, respectively. This indicates that minimally supported designs are only efficient if the bivariate outcomes are weakly correlated. For a strong correlation between efficacy and toxicity, minimally supported designs cannot be recommended. A direct calculation shows the uniform design with dose levels 0·00, 0·35, 1·40, 2·80, 4·20, 5·60, 7·00 has D-efficiencies 0·89, 0·89, 0·88 when ρ = 0·1, 0·5 and 0·9, respectively.
CONCLUSIONS
There are several lines of future research. First, the results of this paper on locally optimal designs require a priori information about the unknown model parameters and an interesting direction is to further develop the methodology to accommodate more sophisticated optimality criteria, which are robust against a misspecification of the unknown parameters. Second, while the mentioned applications typically consider bivariate outcomes, it is also of interest to extend these results to multivariate responses. The results of Mukhopadhyay & Khuri (2008) indicate that such an extension is very challenging. Finally, this paper considers models with additive normally distributed random errors. This assumption is mainly made for the sake of transparent notation, and using similar techniques to those described by Dette et al. (2015) the results can be extended to more general models involving exponential families. On the other hand, a further important and very challenging direction of future research is the development of a corresponding methodology which is applicable in random effect models.
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